

Index

A

- Abdominal pain (AP), 272–273
- Achillea millefolium*. *See* Yarrow
- Acupuncture
 - evidence-based medicine, 255
 - febrile disease, 254
- Acute febrile neutrophilic dermatosis.
 - See* Sweet's syndrome
- Acute lower airway infection
 - asthma, 90–92
 - bronchiolitis, 89–90
 - pneumonia, 92–95
- Acute upper airway infection
 - bacterial tracheitis, 88
 - infectious mononucleosis (IM), 86–87
 - otitis media (OM), 85–86
 - spasmodic croup, 88
 - tonsillopharyngitis, 84–85, 267
 - viral croup, 87–88
 - viral URTI, 82–84
- Acute viral encephalitis, 116
- Amebic liver abscess, 273
- Amoebic dysentery, 100–102
- Amphetamine, 32
- Anise seed, 253
- Antipyretics
 - action mechanisms, 224
 - antipyrine, 237
 - aspirin
 - adverse effects, 233–234
 - pathophysiological abnormalities, 234–235
 - Reye's Syndrome (RS), 235–237
 - associated discomfort, 226
 - characteristics, 224–225
 - chlorpromazine, 237
 - classification, 228
 - concepts, pediatricians, 226
 - dipyrrone, 237
 - febrile seizures, 226
 - fever phobia, 246–247
 - ibuprofen
 - perioperative pain control, 232
 - toxicity, 232–233
 - indications, 225, 242–243
 - indomethacin, 237
 - microorganisms and defense
 - mechanisms, 227
 - naproxen, 237
 - nimesulide, 237
 - paracetamol
 - effects and dose, 228–229
 - overdose, 230–231
 - side effects, 229–230
 - parents' attitude and expectation, 226
 - physical treatment, 238–239
 - salicylamide, 237
 - side effects and fatalities, 227
 - steroid antipyresis, 237–238
- Arabic medicine, 294
- Arginine vasopressin (AVP), 8
- Aromatherapy, 253–254
- Aspiration pneumonia, 95
- Asthma
 - clinical data of, 91
 - severity, 90
 - therapy, 91, 92
- Autoinflammatory disease, 4–5
- Axillary temperature (AT), 70–71

B

- Baclofen, 32
- Bacteremia
causes, 16
management, 17
serious bacterial infection, 16–17
- Bacterial gastroenteritis
amoebic dysentery
Campylobacter enteritis, 101
EIEC and STEC, 101
Entameba histolytica, 100–101
fever and organism excretion in, 99
Salmonellae, 98–99
secretory and invasive pathogens, 97–98
Shigellae role in, 100
treatment, 103
typhoid fever, 99
Yersinia enterocolitica, 101–102
- Bacterial meningitis
causes of, 111
CSF characteristics in, 114
fever in, 112–113
persistent, prolonged, and secondary fevers
causes, 113
treatment, 115
tuberculous meningitis, 112
- Body temperature measurement
axilla
advantages, 70
disadvantages, 71
core temperature, 68
evidence-based measurement, 75–76
home thermometer, 69
instrumentation, 70
oral temperature (OT), 72–73
rectal temperature (RT), 73–74
significance, 67–68
skin, 71
tactile assessment, 69–70
thermometer, 64–67
thermoscope, 64–65, 295
tympanic infrared thermometer, 74–75
- Blood transfusion, febrile reaction, 144–146
- Brain abscess, 116–117
- Bronchiolitis, 89–90
- Brucellosis, 126–127
- C**
- Caffey's disease. *See* Infantile cortical hyperostosis
- Campylobacter enteritis*, 101
- Cancer in fever therapy, 296–297
- Cancer, hyperthermia, 43
- Central nervous system (CNS)
acute viral encephalitis, 116
brain abscess, 116–117
meningitis, 110–115
- Child management, Febrile seizure
acute management, 185
anticonvulsant therapy and recurrences, 187–188
antipyretic agents, 188
EEG, 186
Glasgow Coma score, 185
lumbar puncture (LP), 186
reassurance, parents, 188
routine brain imaging, 186
- Chinese medicine, 290–291
- Chiropractic, 257
- Cocaine, 32
- Cold injury, 197–198
- Coma
bacterial meningitis, 277
herpes simplex encephalitis (HSE)
intracranial abscess, 277
shock and sepsis, 278
TB meningitis, 277–278
- Complimentary medicine, 252
- Critical thermal maximum (CTM), 27
- Crohn's disease, 273
- D**
- Dermatomyositis, 159–160
- Diabetes mellitus, 33
- Drug fever (DF)
definition, 21
diagnostic features, 21–22
drugs in, 22–23
mechanisms, 22
- Drug-induced hyperthermia, 31, 39
- E**
- Ecstasy, 32
- Egyptian medicine, 288
- Elder flowers, 253
- Endocrine hyperthermia (EH), 33–34
- Endogenous pyrogens (EP), 53–56
Entameba histolytica, 100–101
Enteric adenovirus, 102
Enteric fever (Typhoid fever), 99, 273
Enterotoxigenic *E. coli* (EIEC), 101

- Epiglottitis, 88
- Epstein–Barr virus (EBV), 86–87
- Erythema infectiosum (EI), 120–121
- European medicine
- bacteriology, 296
 - temperature measurement, 295
 - “typhus,” 295
- Evidence-based temperature measurement, 75
- Exanthema subitum (ES), 121–122
- Exogenous pyrogens (ExPs)
- fever induction mechanisms, 49–50
 - microbial pyrogens, 50
 - non-microbial pyrogens, 51
- F**
- Factitious hyperthermia (FF), 40–41
- Familial cold urticaria syndrome, 262
- Familial dysautonomia, 169–170
- Familial mediterranean fever, 263
- FCUS. *See* Familial cold urticaria syndrome
- Febrile child, assessment, 239–240, 244
- Febrile diseases, differential diagnosis (DD)
- abdominal pain (AP), 272–273
 - coma, 277–278
 - differentiation
 - fever, infectious and noninfectious origin, 260
 - viral and bacterial infections, 261
 - gastroenteritis, 274
 - hyperthermic conditions, 267
 - inflammatory arthritis (IA)
 - oligoarthritis, 281–282
 - polyarthritis, 281
 - jaundice, 275–276
 - non-blanching rash, child, 280
 - periodic fever
 - familial cold urticaria syndrome (FCUS), 262
 - familial mediterranean fever (FMF), 263
 - Muckle–Wells syndrome (MWS), 262
 - TNF-receptor associated periodic syndrome (TRAPS), 262
 - pharyngitis/tonsillitis, 269
 - pneumonia and chest infiltration
 - Haemophilus influenzae*, 271
 - Mycoplasma* and *Pneumococcal*, 270
 - Pneumocystis carinii*, 271
 - Pulmonary tuberculosis*, 271
 - Staphylococcal*, 270–271
 - postoperative fever, 283
 - seizures, 284–285
 - tropical disease, 279
 - unexplained fever (*see* Pyrexia of unknown origin)
 - unexplained hypothermia, 268
- Febrile illness characterization, Hippocratic writing, 292
- Febrile neutropenia
- causes, 148
 - factors, 147–148
- Febrile seizure (FS) (Chap 7), 175
- bacteraemia, 179
 - child management
 - acute management, 185
 - anticonvulsant therapy and recurrences, 187–188
 - antipyretic agents, 188
 - EEG, 186
 - Glasgow Coma Score, 185
 - lumbar puncture (LP), 186
 - reassurance, parents, 188
 - routine brain imaging, 186
 - clinical features
 - generalised tonic–clonic seizures (GTCS), 180–181
 - myoclonic jerks, 181
 - predisposing factors, 180
 - tonic features, 181
 - definitions, 176
 - differential diagnosis, 182–183
 - epidemiology, 177
 - febrile status, 184–185
 - human herpesvirus (HHV)-6, 179
 - International League Against Epilepsy (ILAE), 176
 - mechanisms
 - genetic factors, 177–178
 - immature brain, 178
 - proinflammatory cytokines, 179
 - prognosis
 - epilepsy, 183–184
 - neurological, learning and behaviour outcomes, 184
 - recurrence risk, 182
- Fever (Chap 1), 1
- acupuncture
 - evidence-based medicine, 255
 - febrile disease, 254
 - acute stroke, 218
 - ancient civilizations
 - Chinese medicine, 290–291
 - Egyptian medicine, 288

- Fever (*cont.*)
- Greek medicine, 291–293
 - Hebrew medicine, 293
 - Hindu medicine, 291
 - Mesopotamian medicine, 288–290
 - antipyretics, 216–217
 - aromatherapy, 253–254
 - bronchiolitis, 218
 - cancer, 296–297
 - chiropractic and osteopathy, 257
 - classification
 - causes of, 10
 - fetal temperature, 11
 - with localized signs, 9–15
 - management, 12–15
 - pyrexia of unknown origin (PUO), 17–20
 - serious bacterial infection (SBI), 11–12, 14
 - without localized signs, 15–17
 - complications, 8–9
 - defense mechanisms, elevated temperature, 213–214
 - definitions, 2
 - drug fever (DF), 21–23
 - European medicine
 - bacteriology, 296
 - temperature measurement, 295
 - “typhus,” 295
 - evolving concepts, 288
 - familial dysautonomia, 169–170
 - familial mediterranean fever (FMF), 167–168
 - febrile seizure, 217
 - fetal malformation
 - congenital defects, 20
 - maternal fever, 20–21
 - fever following vaccination, 164–166
 - fever-producing agents, 211
 - haematology
 - febrile reactions, 144–146
 - homozygous beta-thalasaemia, 140–141
 - iron deficiency (ID) anaemia, 141–142
 - megaloblastic anaemia, 142–154
 - neutropenia (*see also* Febrile neutropenia)
 - sickle cell anaemia (SCA), 138–140
 - warm and cold autoimmune haemolytic anaemia, 141
 - herbal medicine, 252–253
 - homeopathy
 - complimentary medicine, 252
 - holistic system, 251
 - Viburcol medicine, 252
 - hygiene theory, 215
 - hypohidrotic ectodermal dysplasia, 168–169
 - infantile cortical hyperostosis, 170
 - infectious disease, 297
 - limited energy supply, 218
 - manifestations associated with, 6–7
 - massage and shiatsu, 256
 - metabolic cost, 212
 - metabolic effects of, 7–8
 - microorganisms, elevated temperature
 - animal studies, 212–213
 - human studies, 213
 - middle ages
 - anatomical studies, 293
 - Arabic medicine, 294
 - bloodletting, 293–294
 - hot and moist diseases, 293
 - mild discomfort and myalgia, 218
 - neoplastic diseases
 - central nervous system tumours, 154
 - Hodgkin’s disease, 151–152
 - leukaemia, 150–151
 - nephroblastoma, 153–154
 - neuroblastoma, 153
 - parents’ attitude and expectation, 215–216
 - pathogenesis
 - activated lymphocytes, 56–58
 - definitions, 48–49
 - exogenous pyrogens (ExPs), 49–51
 - fever induction steps, 61
 - heat loss, 59–60
 - heat production, 59
 - history, 48
 - interleukin-1, 53–54
 - interleukin-6, 55
 - lymphokines, 56
 - monocyte–macrophage system, 51–52
 - temperature regulation, 60–61
 - tumour necrosis factor, 54–55
 - patterns of
 - genetic periodic fever syndromes, 4–5
 - Jarish–Herxheimer reaction (JHR), 4
 - in pediatric diseases, 3
 - Pel–Ebstein fever, 4
 - periodic and relapsing fever, 3–4
 - pediatricians, prevailing concepts, 216
 - phobia, 246–247
 - postoperative fever, 163–164
 - prostaglandins, 54, 216, 224
 - radical transformation, 287

- reflexology, 255–256
- rheumatic diseases and vasculitis
- Kawasaki disease (KD), 161–163
 - macrophage activation syndrome (MAS), 160–161
 - progressive systemic sclerosis, 160
 - rheumatic fever (RF), 155–156
 - systemic lupus erythematosus (SLE), 158–160
- sarcoidosis, 166–167
- severe sepsis, 218
- spiritual healing, 257–258
- suppression, 214
- sweet's syndrome, 169
- teeth eruption, 170–171
- therapy, history of, 290–291
- thermoregulatory set-point, 212
- T-lymphocytes activation, 297
- vestigial trait, 212
- viral infection, 217
- Feverfew, 252
- Fever management, antipyretics
- action mechanisms, 224
 - antipyrine, 237
 - aspirin
 - adverse effects, 233–234
 - pathophysiological abnormalities, 234, 235
 - Reye's syndrome (RS), 235–237
 - associated discomfort, 226
 - characteristics, 224–225
 - chlorpromazine, 237
 - classification, 228
 - concepts, pediatricians, 226
 - dipyrrone, 237
 - febrile seizures, 226
 - fever phobia, 246–247
 - home
 - antipyretic measures, 244–245
 - febrile child assessment, 244
 - temperature measurement, 243
 - hospital
 - antibiotics usage, guidelines, 243
 - body temperature, 240–241
 - febrile child admission, 241–242
 - febrile child assessment, 239–240
 - ibuprofen
 - perioperative pain control, 232
 - toxicity, 232–233
 - indications, 225
 - indomethacin and salicylamide, 237
 - microorganisms and defense mechanisms, 227
 - naproxen and nimesulide, 237
 - paracetamol
 - effects and dose, 228–229
 - overdose, 230–231
 - side effects, 229–230
 - parents' attitude and expectation, 226
 - physical treatment, 238–239
 - side effects and fatalities, 227
 - steroid antipyresis, 237–238
- FMF. *See* Familial mediterranean fever
- G**
- GABHS. *See* Group A β -hemolytic streptococcus
- Gastroenteritis
- bacterial and viral etiology, 96, 97
 - bacterial gastroenteritis, 97–102
 - dehydration, 96–98
 - enteropathogenic agents, 96
 - febrile non-enteritis diseases, 97
 - viral gastroenteritis, 102–103
- Ginger, 253
- Glycyrrhiza glabra*. *See* Licorice
- Gram-negative bacteria, 50
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 58
- Greek medicine, 291–293
- Group A β -hemolytic streptococcus (GABHS), 269
- H**
- Haematology
- febrile reactions
 - allergic reactions, 146
 - bacterial reactions, 145
 - haemolytic reactions, 144–145
 - non-cardiogenic pulmonary oedema, 146
 - haemolytic anaemia
 - homozygous beta-thalasaemia, 140–141
 - sickle cell anaemia (SCA), 138–140
 - warm and cold autoimmune haemolytic anaemia, 141
 - iron deficiency (ID) anaemia, 141–142
 - megaloblastic anaemia, 142–143
 - neutropenia (*see also* Febrile neutropenia)
 - causes, 143
 - cyclic neutropenia, 144
 - definition, 143
 - risk factors, 144

- Haemophilus influenzae pneumonia*, 93, 271
- Haemorrhagic shock and encephalopathy (HSE), 37–38
- Heat stroke
- cardinal features, 36
 - mechanism, 35
 - risk factors, 35, 36
- Hebrew medicine, 293
- Hepatitis A (HA), 275
- Hepatitis A virus (HAV), 103–104
- Hepatitis B virus (HBV), 104
- Herbal medicine, 252–253
- Herpes labialis, 9
- Herpes simplex encephalitis (HSE), 277–278
- Hindu medicine, 291
- Hodgkin's disease, 151–152
- Homeopathy
- complimentary medicine, 252
 - holistic system, 251
 - Viburcol medicine, 252
- Homozygous beta-thalassaemia, 140–141
- HSE. *See* Herpes simplex encephalitis
- Human immunodeficiency virus (HIV)
- infection
 - diagnosis, 107
 - differential diagnosis, 108, 109
 - fever in, 106, 107
 - laboratory investigations, 107
 - PUO management, 108–110
- Hygiene theory, 215
- Hyperpyrexia, 9
- Hyperthermia, (Chap 2), 25
- causes
 - dehydration, 35
 - drug-induced hyperthermia, 39–40
 - drugs in, 31–32
 - endocrine hyperthermia (EH), 33–34
 - exercise-induced hyperthermia, 32–33
 - haemorrhagic shock and encephalopathy (HSE), 37–38
 - heat stroke, 35–37
 - malignant hyperthermia, 28–30
 - neonatal hyperthermia, 34–35
 - neuroleptic malignant syndrome (NMS), 30–31
 - serotonin syndrome (SS), 31
 - sudden infant death syndrome (SIDS), 38–39
- definition, 25–26
 - effects, 27–28
 - and fever, 26
 - physiology, 26–27
 - therapeutic effects
 - chemotherapy, 43
 - infectious diseases, 43
 - therapeutic application, 42
- unclassified hyperthermia
- factitious hyperthermia (FF), 40
 - induced illness, 40–41
 - proxy induced illness, 41–42
- Hyperthyroidism, 33
- Hypothermia
- definition, 193
 - neonatal
 - cold injury, 197–198
 - early-onset, 196
 - late-onset, 196–197
 - physiological considerations, 194–196
 - prevention, 198–199
 - treatment, 199–200
- older children
- accidental, 201–203
 - CNS lesions, 205
 - drug-induced, 204
 - heat production mechanisms, 200
 - infection, 204
 - main causes, 200–201
 - malnourished children, 205
 - management, 205–207
 - metabolic causes, 205
 - spontaneous, 203
- Osborn J waves, 202
- Shapiro's syndrome, 203
- therapeutic use
- cancer, 208
 - HIE, 207–208
 - neuro and cardiac surgery, 208
- Hypoxic ischemic encephalopathy (HIE), 207
- I**
- Ibuprofen. *See* Antipyretics
- Infantile cortical hyperostosis, 170
- Infectious mononucleosis (IM)
- features and complications, 86
 - therapy, 87
- Inflammatory arthritis (IA). *See also* Juvenile idiopathic arthritis
- oligoarthritis, 281–282
 - polyarthritis, 281
- Interferon (INF), 57

- Interleukin-1 (IL-1)
 antagonism, 54
 functions, 53–54
 production, 53
- Interleukin-2 (IL-2), 58
- Interleukin-6 (IL-6), 55
- International League Against Epilepsy (ILAE), 176
- J**
- Jarish-Herxheimer reaction (JHR), 4
- Jaundice, 275–276
- Juvenile idiopathic arthritis, 156–158
- K**
- Kawasaki Disease, 3, 10, 18, 37, 55, 58, 97, 137, 161, 172, 180, 233, 269, 281, 306
- L**
- Leishmaniasis, 129–130
- Leptospirosis, 128–129
- Leukaemia, 150–151
- Licorice, 253
- Lyme disease (LD), 127–128
- Lymphocytes, 56–57
- M**
- Macrophage activation syndrome (MAS), 160–161
- Malaria
 diagnosis and therapy, 126
 febrile cycle, 125
Plasmodium, 124–125
 prophylaxis and therapy, 126
- Malformation and fever, 20–21
- Malignant hyperthermia (MH)
 risk factors and clinical features, 29
 treatment, 29–30
- Malnutrition and fever, 130
- Measles, 118–119
- Meningitis
 bacterial meningitis
 causes of, 111
 CSF characteristics in, 114
 fever in, 112–113
 persistent, prolonged, and secondary fevers causes, 113
 treatment, 115
Tuberculous meningitis, 112
 in older children, 112
 pathogenesis, 111
 viral meningitis, 115
- Mesopotamian medicine
 cuneiform writing, 289
 pneumonia, 289
 Sumerian pictogram writing, 290
- Microbial pyrogens, 50
- Monocyte–macrophage system (MMS), 51–52
- Muckle-Wells syndrome (MWS), 262
- Musculoskeletal disorders, and therapeutic effects of hyperthermia, 43
- Mycoplasma pneumoniae*, 94–95, 270
- N**
- Naproxen. *See* Antipyretics
- Naproxen test, 148
- Neonatal hypothermia
 cold injury, 197–198
 early-onset and last-onset, 196–197
 physiological considerations
 heat loss, 194–195
 neutral thermal environment (NTE), 194
 risk factors, 195
 prevention, 198–199
 treatment, 199–200
- Neonatal meningitis, 111–112
- Neoplastic arthritis, 282
- Neoplastic diseases
 central nervous system tumours, 154
 febrile neutropenia
 causes, 148
 fever in, 147–148
 Hodgkin's disease, 151–152
 leukaemia, 150–151
 nephroblastoma, 153–154
 neuroblastoma, 153
- Nephroblastoma, 153–154
- Neuroblastoma, 153
- Neuroleptic malignant syndrome (NMS)
 diagnostic criteria, 31
 medications in, 30
- Neutral thermal environment, 194
- Neutropenia fever in, 143–144
- Nimesulide. *See* Antipyretics
- Non-infectious diseases, fever in (Chap 6), 137
 familial dysautonomia, 169–170
 familial mediterranean fever (FMF), 167–168
 fever following vaccination, 164–166
 haematology
 febrile reactions, 144–146
 homozygous beta-thalassaemia, 140–141
 iron deficiency (ID) anaemia, 141–142
 megaloblastic anaemia, 142–154

- Non-infectious diseases, fever in (*cont.*)
 neutropenia (*see also* Febrile neutropenia)
 sickle cell anaemia (SCA), 138–140
 warm and cold autoimmune haemolytic anaemia, 141
 hypohidrotic ectodermal dysplasia, 168–169
 infantile cortical hyperostosis, 170
 neoplastic diseases
 central nervous system tumours, 154
 Hodgkin's disease, 151–152
 leukaemia, 150–151
 neuroblastoma, 153–154
 neuroblastoma, 153
 postoperative fever, 163–164
 rheumatic diseases and vasculitis
 Kawasaki disease (KD), 161–163
 macrophage activation syndrome (MAS), 160–161
 progressive systemic sclerosis, 160
 rheumatic fever (RF), 155–156
 systemic lupus erythematosus (SLE), 158–160
 sarcoidosis, 166–167
 sweet's syndrome, 169
 teeth eruption, 170–171
 Non-microbial pyrogens, 51
 Nontyphoidal salmonellae (NTS), 98
 Neutral thermal environment, 194
 Neutropenia, fever in, 143–144
- O**
 Oral rehydration solution (ORS), 103
 Oral temperature (OT), 72–73
 Organum vasculosum laminae terminalis (OVL), 60
 Osteomyelitis and septic arthritis, 117–118
 Otitis media (OM), 85–86
- P**
 Paracetamol. *See* Antipyretics
 Pel–Ebstein fever, 4
Pneumocystis carinii pneumonia (PCP), 95
 Periodic fever (PF)
 characteristics, 3
 familial cold urticaria syndrome (FCUS), 262
 familial mediterranean fever (FMF), 263
 genetic causes, 5
 Muckle-Wells syndrome (MWS), 262
 TNF-receptor associated periodic syndrome (TRAPS), 262
 Pharyngitis/tonsillitis, 84–85, 269
Pimpinella anisum. *See* Anise seed
Plasmodium falciparum, 139
Pneumococcal pneumonia, 270
 Pneumonia
 age 1 month to 4 years, 94
 age of above 4 years, 94–95
 antibiotic therapy, 95
 diagnosis, 92
 and fever, 93
 newborn infants, 93
 pathogens identification, 92–93
Pneumocystis jiroveci pneumonia, 95
 Postoperative fever, 163, 283
 Procalcitonin (PCT), 260
 Prostaglandin treatment, 22
 Prostaglandins, 54, 224
 Protein-calorie malnutrition (PCM), 130
 Pyrexia. *See* Fever
 Pyrexia of unknown origin (PUO)
 causes, 18–19
 diagnosis, 17–19
 physical examination, 19
- R**
 Rat-bite fever, 4
 Reactive arthritis (ReA), 281–282
 Rectal temperature (RT), 73–74
 Reflexology, 255–256
 Relapsing fever (RF), 3–4
 Relative bradycardia, 7
 Relative tachycardia, 7
 Respiratory tract obstruction, 87–88
 Rheumatic diseases and vasculitis
 Kawasaki disease (KD), 161–163
 macrophage activation syndrome (MAS), 160–161
 progressive systemic sclerosis, 160
 rheumatic fever (RF), 155–156
 systemic lupus erythematosus (SLE), 158–160
 Riley-day syndrome. *See* Familial dysautonomia
Rotavirus, 102
 Rubella, 120
- S**
Salix alba. *See* White willow bark
Salmonellae, gastroenteritis, 98

- Sambucus nigra*. *See* Elder flowers
- Septic arthritis (SA), 281
- Serious bacterial infection (SBI)
 early-onset and late-onset organisms in, 11, 12
 factors in, 14
 symptoms and signs, 12
- Serotonin syndrome (SS), 31
- Shapiro's syndrome. *See* Hypothermia
- Shiatsu, 256
- Shigatoxin-producing *E. coli* (STEC), 101
- Shigella gastroenteritis, 100
- Sickle cell anaemia, 138–140
- Spiritual healing, 257–258
- Staphylococcal pneumonia*, 270–271
- Steroid antipyresis, 237–238
- Streptococcal tonsillopharyngitis*, 84–85
- Subacute sclerosing panencephalitis (SSPE), 116
- Sudden infant death syndrome (SIDS)
 definition, 38
 and hyperthermia, 38–39
 risk factors, 39
- Sweet's syndrome, 169
- T**
- Teeth eruption, fever with, 170–171
- Temperature measurement
 axillary, 70–71
 core, 68
 evidence-based, 75–76
 oral (sublingual), 72–73
 rectal, 73–74
 tympanic, 74–75
- Tepid sponging, 238–239
- Tanacetum parthenium*. *See* Feverfew
- TB arthritis, 282
- T cells, 56–57
- Thalasaemia major. *See* Homozygous beta-thalasaemia
- Thermometer
 anatomical site in, 66
 Celsius and Fahrenheit scales comparison, 66
 history of, 64–67
 thermoscope, 65
- Thermoregulation
 in CNS, 60
 heat production and heat loss, 59–60
- TNF-receptor associated periodic syndrome (TRAPS), 262
- Tonsillopharyngitis, 84–85
- Transient synovitis, 282
- TRAPS. *See* TNF-receptor associated periodic syndrome
- Tropical diseases, 121–130, 279
 brucellosis, 126–127
 fever and malnutrition, 130
 leishmaniasis, 129–130
 leptospirosis, 128–129
 lyme disease (LD), 127–128
 malaria, 124–126
 tuberculosis, 121–123
- Tuberculosis
 diagnosis, 123
 fever in, 123
 miliary, 123
 neonatal, 122
- Tumour necrosis factor (TNF), 54–55
- Tympanic thermometry (TT), 74–75, 77
- U**
- Upper respiratory tract infection (URTI), 82–87
 differential diagnosis, 83, 267
 fever in, 82–83
 fever resolution time, 84
 recommendations, 83
 viruses, 82
- Urinary tract infection (UTI)
 diagnosis of, 105–106
 fever in, 106
 organisms in, 105
 therapy, 106
- V**
- Vaccination, fever with, 164–166
- Varicella, 119–120
- Viral exanthems
 erythema infectiosum (EI), 120–121
 exanthema subitum (ES), 121
 measles, 118–119
 rubella virus, 120
 varicella, 119–120
- Viral gastroenteritis
Enteric adenovirus, 102
 Norfolk virus and Norwalk-like viruses, 102–103
Rotavirus infection, 102
 treatment, 103
- Viral hepatitis
 hepatitis A (HAV), 103–104
 hepatitis B (HBV), 104
- Viral meningitis, 115

W

White willow bark, 253

Wilms' tumour. *See* Nephroblastoma

Y

Yarrow, 253

Yersinia enterocolitica, 101–102

Z

Zingiber officinale roscoe. *See*

Ginger